Motilal Oswal Financial Services neutral on Divi's Laboratories, target price-Rs 2620
Promoters held 51.94 per cent stake in the company as of 31-Dec-2022, while FIIs owned 15.15 per cent, DIIs 20.5 per cent.
By ETMarkets.com | Updated:
iStock
Motilal Oswal Financial Services has neutral call on Divi's Laboratories with a target price of Rs 2620. The current market price of Divi's Laboratories is Rs 2808.
Divi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 74105.55 Crore) operating in Pharmaceuticals sector.
Divi's Laboratories key Products/Revenue Segments include Pharmaceuticals, Scrap, Export Incentives and Contract Fees for the year ending 31-Mar-2022.
Financials
For the quarter ended 31-12-2022, the company has reported a Consolidated Total Income of Rs 1821.93 Crore, down -5.82 % from last quarter Total Income of Rs 1934.62 Crore and down -27.41 % from last year same quarter Total Income of Rs 2509.86 Crore. Company has reported net profit after tax of Rs 306.80 Crore in latest quarter.
The company’s top management includes Dr.Ramesh B V Nimmagadda, Dr.S Ganapaty, Prof.Sunaina Singh, Mr.R Ranga Rao, Dr.G Suresh Kumar, Mr.K V K Seshavataram, Mr.N V Ramana, Mr.Madhusudana Rao Divi, Ms.Nilima Prasad Divi, Dr.Kiran S Divi, Dr.Murali K Divi, Mr.K V Chowdary. Company has Price Waterhouse Chartered Accountants LLP as its auditors. As on 31-12-2022, the company has a total of 27 Crore shares outstanding.
The brokerage factors 260bp margin expansion over FY23-FY25, led by reducing cost drag, scaleup of custom synthesis business in contrast media/peptide category as well as sartans/other new molecules in API business.
Promoter/FII Holdings
Promoters held 51.94 per cent stake in the company as of 31-Dec-2022, while FIIs owned 15.15 per cent, DIIs 20.5 per cent.
Divi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 74105.55 Crore) operating in Pharmaceuticals sector.
Divi's Laboratories key Products/Revenue Segments include Pharmaceuticals, Scrap, Export Incentives and Contract Fees for the year ending 31-Mar-2022.
Financials
For the quarter ended 31-12-2022, the company has reported a Consolidated Total Income of Rs 1821.93 Crore, down -5.82 % from last quarter Total Income of Rs 1934.62 Crore and down -27.41 % from last year same quarter Total Income of Rs 2509.86 Crore. Company has reported net profit after tax of Rs 306.80 Crore in latest quarter.
The company’s top management includes Dr.Ramesh B V Nimmagadda, Dr.S Ganapaty, Prof.Sunaina Singh, Mr.R Ranga Rao, Dr.G Suresh Kumar, Mr.K V K Seshavataram, Mr.N V Ramana, Mr.Madhusudana Rao Divi, Ms.Nilima Prasad Divi, Dr.Kiran S Divi, Dr.Murali K Divi, Mr.K V Chowdary. Company has Price Waterhouse Chartered Accountants LLP as its auditors. As on 31-12-2022, the company has a total of 27 Crore shares outstanding.
ADVERTISEMENT
Investment RationaleThe brokerage factors 260bp margin expansion over FY23-FY25, led by reducing cost drag, scaleup of custom synthesis business in contrast media/peptide category as well as sartans/other new molecules in API business.
Promoter/FII Holdings
Promoters held 51.94 per cent stake in the company as of 31-Dec-2022, while FIIs owned 15.15 per cent, DIIs 20.5 per cent.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
